Long-Term Use of Tedizolid in Osteoarticular Infections: Benefits among Oxazolidinone Drugs

Background: To evaluate the efficacy and safety of long-term use of tedizolid in osteoarticular infections. Methods: Multicentric retrospective study (January 2017–March 2019) of osteoarticular infection cases treated with tedizolid. Failure: clinical worsening despite antibiotic treatment or the need of suppressive treatment. Results: Cases (n = 51; 59% women, mean age of 65 years) included osteoarthritis (n = 27, 53%), prosthetic joint infection (n = 17, 33.3%), and diabetic foot infections (n = 9, 18%); where, 59% were orthopedic device-related. Most frequent isolates were Staphylococcus spp. (65%, n = 47; S. aureus, 48%). Reasons for choosing tedizolid were potential drug-drug interaction (63%) and cytopenia (55%); median treatment duration was 29 days (interquartile range -IQR- 15–44), 24% received rifampicin (600 mg once daily) concomitantly, and adverse events were scarce (n = 3). Hemoglobin and platelet count stayed stable throughout treatment (from 108.6 g/L to 116.3 g/L, p = 0.079; and 240 × 109/L to 239 × 109/L, p = 0.942, respectively), also in the subgroup of cases with cytopenia. Among device-related infections, 33% were managed with implant retention. Median follow-up was 630 days and overall cure rate 83%; among failures (n = 8), 63% were device-related infections. Conclusions: Long-term use of tedizolid was effective, showing a better safety profile with less myelotoxicity and lower drug-drug interaction than linezolid. Confirmation of these advantages could make tedizolid the oxazolidinone of choice for most of osteoarticular infections.

[1]  M. Salavert Lletí,et al.  Safety and Tolerability of More than Six Days of Tedizolid Treatment , 2020, Antimicrobial Agents and Chemotherapy.

[2]  R. Kullar,et al.  Retrospective Real-World Evaluation of Outcomes in Patients with Skin and Soft Structure Infections Treated with Tedizolid in an Outpatient Setting , 2020, Infectious Diseases and Therapy.

[3]  C. Carvalhaes,et al.  Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17). , 2019, The Journal of antimicrobial chemotherapy.

[4]  E. Peters,et al.  IWGDF Guideline on the diagnosis and treatment of foot infection in persons with diabetes , 2019 .

[5]  Mikhail A. Dziadzko,et al.  Correction of Linezolid-Induced Myelotoxicity After Switch to Tedizolid in a Patient Requiring Suppressive Antimicrobial Therapy for Multidrug-Resistant Staphylococcus epidermidis Prosthetic-Joint Infection , 2018, Open forum infectious diseases.

[6]  S. Liang,et al.  Successful Treatment of Prosthetic Joint Infection Due to Vancomycin-Resistant Enterococci With Tedizolid , 2017, Infectious diseases in clinical practice.

[7]  Robin Patel,et al.  Activity of Tedizolid in Methicillin-Resistant Staphylococcus epidermidis Experimental Foreign Body-Associated Osteomyelitis , 2016, Antimicrobial Agents and Chemotherapy.

[8]  S. Flanagan,et al.  Characterization of the haematological profile of 21 days of tedizolid in healthy subjects. , 2016, The Journal of antimicrobial chemotherapy.

[9]  Robin Patel,et al.  Activity of Tedizolid in Methicillin-Resistant Staphylococcus aureus Experimental Foreign Body-Associated Osteomyelitis , 2016, Antimicrobial Agents and Chemotherapy.

[10]  J. Briegel,et al.  Decreased Linezolid Serum Concentrations in Three Critically Ill Patients: Clinical Case Studies of a Potential Drug Interaction between Linezolid and Rifampicin , 2016, Pharmacology.

[11]  R. Stahlmann,et al.  Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones , 2015, Expert opinion on drug metabolism & toxicology.

[12]  M. Gilmour,et al.  Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens , 2015, Drugs.

[13]  P. Tulkens,et al.  Nonclinical and Pharmacokinetic Assessments To Evaluate the Potential of Tedizolid and Linezolid To Affect Mitochondrial Function , 2014, Antimicrobial Agents and Chemotherapy.

[14]  Á. Soriano,et al.  Clinical experience with linezolid for the treatment of orthopaedic implant infections. , 2014, The Journal of antimicrobial chemotherapy.

[15]  G. Moran,et al.  Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. , 2014, The Lancet. Infectious diseases.

[16]  S. Flanagan,et al.  Single- and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid , 2014, Pharmacotherapy.

[17]  D. Paterson,et al.  Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid , 2014, Antimicrobial Agents and Chemotherapy.

[18]  J. Ariza,et al.  Linezolid in late-chronic prosthetic joint infection caused by gram-positive bacteria. , 2013, Diagnostic microbiology and infectious disease.

[19]  S. Flanagan,et al.  In Vitro, In Vivo, and Clinical Studies of Tedizolid To Assess the Potential for Peripheral or Central Monoamine Oxidase Interactions , 2013, Antimicrobial Agents and Chemotherapy.

[20]  Anita F. Das,et al.  Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. , 2013, JAMA.

[21]  A. Hanssen,et al.  Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  F. Pea,et al.  Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. , 2012, The Journal of antimicrobial chemotherapy.

[23]  R Scott Obach,et al.  Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its Mechanism , 2011, Journal of clinical pharmacology.

[24]  Y. Yazdanpanah,et al.  Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia? , 2010, The Journal of antimicrobial chemotherapy.

[25]  Y. Yazdanpanah,et al.  Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. , 2006, Clinical therapeutics.

[26]  John W. Wilson,et al.  Linezolid and serotonergic drug interactions: a retrospective survey. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  S. Grau,et al.  Linezolid-associated serotonin syndrome: what we can learn from cases reported so far. , 2005, The Journal of antimicrobial chemotherapy.

[28]  K. Kümmerer,et al.  Linezolid and Rifampin: Drug Interaction Contrary to Expectations? , 2005, Clinical pharmacology and therapeutics.

[29]  S. Gerson,et al.  Hematologic Effects of Linezolid: Summary of Clinical Experience , 2002, Antimicrobial Agents and Chemotherapy.